✦ LIBER ✦

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

✍ Scribed by Avet-Loiseau, H; Soulier, J; Fermand, J-P; Yakoub-Agha, I; Attal, M; Hulin, C; Garderet, L; Belhadj, K; Dorvaux, V; Minvielle, S

Book ID: 109887026
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 313 KB
Volume: 24
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2009.273

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Impact of prior therapies on the relativ

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

✍ Dan T. Vogl; Edward A. Stadtmauer; Paul G. Richardson; Pieter Sonneveld; Michael 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB

Long-term follow-up on overall survival

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

✍ Dimopoulos, M A; Chen, C; Spencer, A; Niesvizky, R; Attal, M; Stadtmauer, E A; P 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 164 KB